Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): February 8, 2011
 
 
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
  
001-33038
  
84-1475672
(State or Other Jurisdiction of Incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
 
1180 Avenue of the Americas
19th Floor
New York, NY
  
10036
(Address of Principal Executive Offices)
  
(Zip Code)
 
(646) 214-0700
(Registrant’s telephone number, including area code)
 
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
   
 
 
 

Item 8.01 
Other Events.

On February 8, 2011, ZIOPHARM Oncology, Inc. (the “Company”) completed a public offering of 9,600,000 shares of its common stock.  In connection with the closing, Barclays Capital Inc., the sole book-running manager for the offering, exercised in full its option to purchase an additional 1,440,000 shares, resulting in ZIOPHARM issuing a total of 11,040,000 shares at the closing. The net proceeds from the offering were approximately $59.4 million after deducting underwriting discounts and estimated offering expenses. 
 
On February 8, 2011, the Company issued a press release announcing the completion of the offering and the underwriter’s full exercise of its option to purchase additional shares.  The press release is attached as Exhibit 99.1.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) 
Exhibits                         
 
Exhibit No. 
Description
 
99.1 
Press release dated February 8, 2011
 
 
 
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
ZIOPHARM Oncology, Inc.
  
     
       
Date: February 8, 2011
By:
/s/ Richard Bagley  
   
Name: Richard Bagley
  
   
Title: President, Chief Operating Officer and Chief Financial Officer
  
       
 
 
 
 

INDEX OF EXHIBITS
 
Exhibit No.
  
Description
     
99.1
  
Press release dated February 8, 2011